ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]
Attend the National Research Symposium & Gluten-Free EXPO June 3-4, 2017 Register Today
We fight to improve the lives of all affected by celiac disease and non-celiac gluten/wheat sensitivity NOW
In 1992, M.N. Marsh published a study aimed at measuring degrees of change seen in the structure of intestinal villi under microscopic scrutiny. Villi are finger-like projections which line the intestinal walls; their thin walls and large surface area are what allow for efficient absorption and digestion of nutrients. In patients with celiac disease, the […]
In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.
Patients with chronic diseases and their caregivers are demanding that any new health plan that emerges from Congress retains specific patient protections, including prohibiting pre-existing condition discrimination.
Celiac Disease Foundation (CDF) and the North American Society for the Study of Celiac Disease (NASSCD) are proud to announce Matthew Shale, MD, PhD as the recipient of the Young Investigator Award.
Celiac Disease Foundation has launched a new Legislative Action Center to empower you, your family, and your friends to quickly and easily contact your elected Representatives about issues of concern to the celiac disease and non-celiac wheat/gluten sensitive community. We are urging you to use the Legislative Action Center right now to demand that your […]